This is evidenced by strong effects on proliferation and expression of POU2F3 and its coactivators upon BRD9 degradation (using FHD-609, WA-68-VQ71, or dBRD9A) on non-neuroendocrine POU2F3+ SCLC models, and pan-SWI/SNF ATPase inhibition or degradation (using FHD-286, BRM014 and AU-15330) on all POU2F3+ cells (Figure 5A) (Duplaquet et al., 2024). The gene discussed is DNAH8; the disease is small cell lung carcinoma.